Precision medicine for children with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance outcomes for childhood cancer patients by implementing precision medicine approaches. It will utilize comprehensive molecular profiling and preclinical drug testing in real-time for high-risk patients, while also exploring the role of precision medicine in diagnosing and stratifying risk in non-high-risk childhood cancers. The study will extend the ZERO platform to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine across various childhood cancer types and risk groups through integrative tumor-germline whole genome sequencing analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \< 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.
2. Life expectancy \>6 weeks at time of enrolment
3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.

Where it's running

• Women's and Children's Hospital
  Adelaide, Australia Recruiting
• Queensland Children's Hospital
  Brisbane, Australia Recruiting
• Royal Hobart Hospital
  Hobart, Australia Recruiting
• Monash Children's Hospital
  Melbourne, Australia Recruiting
• Royal Children's Hospital
  Melbourne, Australia Recruiting
• John Hunter Children's Hospital
  Newcastle, Australia Recruiting

Study contacts

• Principal investigator: David Ziegler — Schn
• Study coordinator: National Study Coordinator
• Email: SCHN-ZERO2@health.nsw.gov.au
• Phone: +61 2 9382 3102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted therapies for childhood and adolescent cancer

  This study is testing if new targeted treatments based on the genetic makeup of tumors can help kids and teens with cancer feel better and improve their chances of recovery.

  Recruiting at 12 sites Phase 1/2 Australian & New Zealand Children's Haematology/Oncology Group · Newcastle, New South Wales and 13 other locations · NCT06208657

• Blood biomarkers for treatment-related brain injury in children with brain tumors

  This project will test whether blood plasma biomarkers can show treatment-related brain injury in children with primary brain tumors by comparing those who receive radiotherapy, those who do not, and healthy children of the same age and sex.

  Recruiting Uppsala University · Uppsala · NCT07381959

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Outpatient teclistamab treatment plan for relapsed or refractory multiple myeloma

  This pilot will try giving teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient clinic to see if it can be delivered safely and practically while measuring effects on caregivers.

  Recruiting Phase 4 University Health Network, Toronto · Toronto, Ontario · NCT06251076

• Combination therapy for relapsed large cell lymphoma using epcoritamab and chemotherapy

  This study is testing a new combination of treatments for people with relapsed large cell lymphoma to see if it helps them respond better after previous therapies.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05852717

• Combining zanubrutinib and pemetrexed for treating relapsed or refractory CNS lymphomas

  This study is testing if combining two medications, zanubrutinib and pemetrexed, can help people with relapsed or stubborn central nervous system lymphomas feel better and live longer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT05681195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.